95 related articles for article (PubMed ID: 16174457)
1. [Experimental gene therapy mediated by fractalkine (FK) for murine liver cancer].
Tang L; Hu P; Hu HD; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2005 Sep; 13(9):675-7. PubMed ID: 16174457
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L; Hu HD; Hu P; Lan YH; Peng ML; Chen M; Ren H
Gene Ther; 2007 Aug; 14(16):1226-34. PubMed ID: 17597794
[TBL] [Abstract][Full Text] [Related]
3. [Active immunity for anti-colorectal cancer induced by chemokine MCP-3 gene transfection].
Hu JY; Li GC; Zhu JG; Wang WM; Li YH; Zhou GH; Sun QB
Ai Zheng; 2002 May; 21(5):504-8. PubMed ID: 12452041
[TBL] [Abstract][Full Text] [Related]
4. [Induction of anti-hepatocellular carcinoma immunity by Hyper-IL-6 gene in vivo].
Qie CH; Li ST; Cao WK; Lu W; Liang SR
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Sep; 28(9):899-902. PubMed ID: 22980649
[TBL] [Abstract][Full Text] [Related]
5. [Combination therapy of murine liver cancer with IL-12 gene and HSV-TK gene].
Tang Z; Sun W; Chen S
Zhonghua Zhong Liu Za Zhi; 1999 Sep; 21(5):332-5. PubMed ID: 11776567
[TBL] [Abstract][Full Text] [Related]
6. [Combination therapy of experimental murine hepatoma with mIL-12 gene and MHC I gene mediated by liposome].
Wang KM; Xia AD; Chen SS
Ai Zheng; 2002 Oct; 21(10):1041-6. PubMed ID: 12508639
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
8. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma.
Hu P; Hu HD; Chen M; Peng ML; Tang L; Tang KF; Matsui M; Belladonna ML; Yoshimoto T; Zhang DZ; Xiang R; Ren H
Mol Immunol; 2009 May; 46(8-9):1654-62. PubMed ID: 19299021
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells.
Xin H; Kikuchi T; Andarini S; Ohkouchi S; Suzuki T; Nukiwa T; Huqun ; Hagiwara K; Honjo T; Saijo Y
Eur J Immunol; 2005 May; 35(5):1371-80. PubMed ID: 15789339
[TBL] [Abstract][Full Text] [Related]
10. [Combined gene therapy for murine liver cancer with interleukin-18 and cytosine deaminase genes].
Sun W; Tang Z; Wei D; Tang Y; Chen S
Zhonghua Gan Zang Bing Za Zhi; 2001 Oct; 9(5):300-2. PubMed ID: 11676879
[TBL] [Abstract][Full Text] [Related]
11. [Gene therapy for murine liver cancer by adenovirus-mediated cytosine deaminase gene].
Sun W; Wei D; Tang Z; Chen S
Zhonghua Gan Zang Bing Za Zhi; 2000 Oct; 8(5):282-4. PubMed ID: 11058952
[TBL] [Abstract][Full Text] [Related]
12. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients.
Ohta M; Tanaka F; Yamaguchi H; Sadanaga N; Inoue H; Mori M
Int J Oncol; 2005 Jan; 26(1):41-7. PubMed ID: 15586223
[TBL] [Abstract][Full Text] [Related]
13. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X
Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector.
Gao JQ; Tsuda Y; Katayama K; Nakayama T; Hatanaka Y; Tani Y; Mizuguchi H; Hayakawa T; Yoshie O; Tsutsumi Y; Mayumi T; Nakagawa S
Cancer Res; 2003 Aug; 63(15):4420-5. PubMed ID: 12907614
[TBL] [Abstract][Full Text] [Related]
15. Fractalkine mediates natural killer-dependent antitumor responses in vivo.
Lavergne E; Combadière B; Bonduelle O; Iga M; Gao JL; Maho M; Boissonnas A; Murphy PM; Debré P; Combadière C
Cancer Res; 2003 Nov; 63(21):7468-74. PubMed ID: 14612547
[TBL] [Abstract][Full Text] [Related]
16. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.
Zeng Y; Jiang J; Huebener N; Wenkel J; Gaedicke G; Xiang R; Lode HN
Cancer Lett; 2005 Oct; 228(1-2):187-93. PubMed ID: 15953676
[TBL] [Abstract][Full Text] [Related]
17. [Nanoparticle-mediated endostatin gene therapy targeting hepatocellular carcinoma utilizing heat-inducible promoter].
Zhou JJ; Chen RF; Li ZH; Zhou QB; Tang QB; He XY; Lu HW; Guo N
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):795-9. PubMed ID: 19595115
[TBL] [Abstract][Full Text] [Related]
18. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
19. Fractalkine protein localization and gene expression in mouse brain.
Tarozzo G; Bortolazzi S; Crochemore C; Chen SC; Lira AS; Abrams JS; Beltramo M
J Neurosci Res; 2003 Jul; 73(1):81-8. PubMed ID: 12815711
[TBL] [Abstract][Full Text] [Related]
20. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1.
Guo J; Chen T; Wang B; Zhang M; An H; Guo Z; Yu Y; Qin Z; Cao X
Immunol Lett; 2003 Oct; 89(1):1-7. PubMed ID: 12946858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
